| Phase 1/2 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 1/2 | ||||
| NCT07631325 | Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma | Unresectable Cutaneous Melanoma | Not Yet Recruiting | 2026-07-13 |
| Not specified | ||||
| NCT06599619 | Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi | Melanoma | Recruiting | 2026-01-26 |
| NCT07223411 | Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and… | Locally Advanced Melanoma | Recruiting | 2025-11-26 |
Melanoma (3)